Acadia Pharmaceuticals (ACAD) Leases: 2019-2025
Historic Leases for Acadia Pharmaceuticals (ACAD) over the last 7 years, with Sep 2025 value amounting to $49.7 million.
- Acadia Pharmaceuticals' Leases rose 12.25% to $49.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.7 million, marking a year-over-year increase of 12.25%. This contributed to the annual value of $46.6 million for FY2024, which is 10.19% down from last year.
- Per Acadia Pharmaceuticals' latest filing, its Leases stood at $49.7 million for Q3 2025, which was down 2.58% from $51.0 million recorded in Q2 2025.
- In the past 5 years, Acadia Pharmaceuticals' Leases ranged from a high of $63.1 million in Q1 2021 and a low of $44.3 million during Q3 2024.
- Moreover, its 3-year median value for Leases was $51.0 million (2025), whereas its average is $50.7 million.
- Its Leases has fluctuated over the past 5 years, first spiked by 678.82% in 2021, then decreased by 12.82% in 2024.
- Quarterly analysis of 5 years shows Acadia Pharmaceuticals' Leases stood at $58.3 million in 2021, then decreased by 4.63% to $55.6 million in 2022, then declined by 6.69% to $51.9 million in 2023, then dropped by 10.19% to $46.6 million in 2024, then climbed by 12.25% to $49.7 million in 2025.
- Its Leases was $49.7 million in Q3 2025, compared to $51.0 million in Q2 2025 and $50.6 million in Q1 2025.